AptarGroup Dirección
Dirección controles de criterios 4/4
El CEO de AptarGroup es Stephan Tanda , nombrado en Feb 2017, tiene una permanencia de 9.25 años. compensación anual total es $10.23M, compuesta por 11.5% salario y 88.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.38% de las acciones de la empresa, por valor de $28.55M. La antigüedad media del equipo directivo y de la junta directiva es de 7.5 años y 7.6 años, respectivamente.
Información clave
Stephan Tanda
Chief Executive Officer (CEO)
US$10.2m
Compensación total
| Porcentaje del salario del CEO | 11.49% |
| Permanencia del CEO | 9.3yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 7.5yrs |
| Promedio de permanencia en la Junta Directiva | 7.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Actualización de narrativa • May 12
ATR: Refillable Beauty And Nasal Drug Delivery Will Support Upside Potential
AptarGroup's updated analyst price target has edged down by about $1.54 to reflect slightly higher discount rate assumptions, along with modest adjustments to projected revenue growth, profit margins, and future P/E expectations, according to analysts. What's in the News AptarGroup and Clarins rolled out a custom reloadable airless packaging solution for Clarins Total Eye Lift Eye Cream, using Aptar Beauty’s patented Gaïa technology to support lower material usage while maintaining formula protection and a premium look.Artículo de análisis • May 03
Analyst Estimates: Here's What Brokers Think Of AptarGroup, Inc. (NYSE:ATR) After Its First-Quarter Report
Shareholders might have noticed that AptarGroup, Inc. ( NYSE:ATR ) filed its first-quarter result this time last week...
Actualización de narrativa • Apr 28
ATR: Nasal Therapies And Share Buybacks Will Support Future Upside
Analysts have kept their $144.00 price target on AptarGroup unchanged, citing relatively steady assumptions around discount rate, revenue growth, profit margin, and future P/E. These factors support the view that the stock’s current valuation framework still holds.Actualización de narrativa • Apr 14
ATR: Nasal Drug Delivery Pipeline And Leadership Transition Will Shape Future Upside
Analysts have reaffirmed AptarGroup's price target at $144.00, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that together suggest a steady view of the company’s valuation. What's in the News AptarGroup’s Unidose Powder Nasal Spray System is being used in ENA Respiratory’s Phase II study of INNA-051, an investigational once-weekly nasal spray aimed at helping protect adults at higher risk from symptomatic viral respiratory infections (Key Developments).Actualización de narrativa • Mar 30
ATR: Nasal And Eye Care Drug Delivery Will Drive Future Upside
Analysts have raised their price target on AptarGroup from $133 to $144. This reflects updated views on its fair value based on revised assumptions for discount rate, revenue growth, profit margin, and future P/E.Actualización de narrativa • Mar 16
ATR: Share Repurchases Will Support Upside Potential In Drug Delivery Portfolio
Analysts have modestly revised their price target on AptarGroup, keeping fair value steady at about $212.79 while fine tuning assumptions on discount rate, revenue growth, profit margin and future P/E. This reflects updated views on the company’s risk profile and earnings potential.Actualización de narrativa • Mar 02
ATR: Share Repurchases And Nasal Drug Delivery Portfolio Will Support Upside Potential
Analysts have trimmed their price target on AptarGroup slightly to about $213, reflecting updated assumptions around a modestly higher discount rate, a small change in estimated fair value and adjusted expectations for revenue growth, profit margins and future P/E levels. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.
Actualización de narrativa • Feb 16
ATR: Drug Delivery Platforms And Buybacks Will Support Attractive Future Returns
Analysts have raised their price target for AptarGroup to $161.43 from $159.14, reflecting updated views on the company’s discount rate, revenue growth assumptions, profit margin outlook, and future P/E expectations. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.Actualización de narrativa • Feb 02
ATR: Nasal And Eye Care Drug Delivery Platforms Will Support Balanced Outlook
AptarGroup's analyst price target has changed from US$153 to US$133 as analysts incorporate updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News AptarGroup's LuerVax and Spray Divider nasal delivery systems are being used in CastleVax's Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate that is being assessed against an FDA approved injectable mRNA vaccine in around 200 U.S. adults, including higher risk and older participants (Key Developments).Actualización de narrativa • Jan 19
ATR: Nasal And Eye Drug Delivery Platforms Will Support Attractive Future Returns
Analysts have trimmed their price target on AptarGroup to about $159 from roughly $161, reflecting slightly adjusted assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that remain broadly consistent with prior views. What's in the News AptarGroup’s nasal vaccine delivery systems, LuerVax and Spray Divider, are being used in CastleVax’s Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate assessing safety, tolerability and immune response versus an FDA approved injectable mRNA vaccine in about 200 U.S. adults, including higher risk and older participants (Key Developments).Actualización de narrativa • Jan 05
ATR: Pharma Nasal Delivery Momentum Will Drive Attractive Long Term Returns
Narrative Update on AptarGroup Analyst Price Target Analysts have modestly raised their price target for AptarGroup to approximately 161.43 dollars, reflecting slightly higher long term return expectations and a marginally richer future earnings multiple. What's in the News Aptar's Bidose liquid nasal spray system has been selected to deliver the newly FDA approved CARDAMYST nasal spray for acute PSVT episodes in adults, which underscores Aptar's role in emergency cardiovascular therapies (FDA announcement) The company completed a 1.50 million share repurchase, about 2.27 percent of shares outstanding, for approximately 227.34 million dollars under its October 2024 buyback program, which signals continued capital return to shareholders (company disclosure) Nasus Pharma extended and updated its long running collaboration with Aptar through a new master services agreement that covers development, analytical, regulatory, and consulting support for its intranasal epinephrine program using Aptar's unit dose powder nasal delivery system (Nasus Pharma announcement) A new supply agreement makes Aptar France the exclusive provider of UDSp devices to Nasus Pharma for its intranasal epinephrine products, with milestone payments and royalties tied to NDA submission, approval, and commercial sales (Nasus Pharma announcement) Valuation Changes Fair value estimate: unchanged at approximately 161.43 dollars per share, indicating no revision to the intrinsic value assessment.Artículo de análisis • Jan 02
We Like These Underlying Return On Capital Trends At AptarGroup (NYSE:ATR)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...Actualización de narrativa • Dec 15
ATR: Share Repurchases And Nasal Drug Delivery Partnership Will Support Upside Potential
Narrative Update Analysts have modestly reduced their price target on AptarGroup, trimming fair value expectations from approximately $220.00 to about $213.03. They cite updated assumptions for slower revenue growth, slightly lower profit margins, and a higher future price to earnings multiple within their discounted cash flow framework.Actualización de narrativa • Nov 30
ATR: Share Buyback and Expanded Pharma Partnerships Will Drive Future Upside
Analysts have slightly raised their price target for AptarGroup to $161.43, citing a modest increase in expected profit margins as well as an updated outlook on revenue growth and future price-to-earnings ratios. What's in the News Between July and September 2025, AptarGroup completed the repurchase of over 1.5 million shares for approximately $227.34 million as part of its ongoing buyback program (Company Filing).Actualización de narrativa • Nov 16
ATR: Share Buyback and Pharma Supply Moves Will Unlock Upside
Narrative Update on AptarGroup Price Target Analysts have revised AptarGroup’s fair value estimate downward by approximately $9 to $161.43 per share, citing tempered growth projections and a modest increase in the discount rate as key factors behind the adjustment. What's in the News Completed share repurchases totaling 1,504,552 shares for $227.34 million under the buyback announced on October 10, 2024 (Buyback Tranche Update).Seeking Alpha • Nov 02
AptarGroup: Pharma Setback Creates Long-Term Opportunities
Summary AptarGroup's shares have dropped over 25% from summer highs due to slower growth, especially in high-margin pharma emergency solutions. ATR's valuation has compressed from 26x to 20x earnings, reflecting concerns about flat growth and a soft outlook for 2026. Pharma remains the most profitable segment, but headwinds in emergency-use delivery systems are expected to impact revenues next year. While the stock is approaching attractive valuation territory, risks remain for earnings growth in 2026, making the opportunity reasonable but not extremely compelling yet. Read the full article on Seeking AlphaActualización de narrativa • Nov 01
ATR: Expanded Partnership Agreements Will Drive Long-Term Healthcare Solutions
Analysts have revised their price target for AptarGroup downward from $177 to $170.71. They cited modest changes in discount rate expectations, a slight increase in projected revenue growth, and softer projected profit margins and future valuation multiples.Artículo de análisis • Oct 18
AptarGroup (NYSE:ATR) Is Increasing Its Dividend To $0.48
The board of AptarGroup, Inc. ( NYSE:ATR ) has announced that it will be increasing its dividend by 6.7% on the 13th of...Actualización de narrativa • Sep 05
Advanced Drug Delivery And Sustainable Packaging Will Transform Global Healthcare
The uptick in AptarGroup’s consensus price target to $178.43 is primarily driven by a modest increase in its forward P/E multiple, while revenue growth expectations remain stable. What's in the News Held Analyst/Investor Day.Artículo de análisis • Aug 28
AptarGroup, Inc.'s (NYSE:ATR) Business Is Trailing The Market But Its Shares Aren't
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...Artículo de análisis • Jul 15
AptarGroup's (NYSE:ATR) Dividend Will Be $0.45
AptarGroup, Inc. ( NYSE:ATR ) will pay a dividend of $0.45 on the 14th of August. The dividend yield is 1.1% based on...Artículo de análisis • Jul 02
Are Investors Undervaluing AptarGroup, Inc. (NYSE:ATR) By 28%?
Key Insights AptarGroup's estimated fair value is US$220 based on 2 Stage Free Cash Flow to Equity Current share price...Artículo de análisis • Jun 19
These 4 Measures Indicate That AptarGroup (NYSE:ATR) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Seeking Alpha • Dec 02
AptarGroup Has Gotten Too Expensive
Summary AptarGroup specializes in niche packaging solutions for pharmaceuticals, beauty, food, and personal care, with impressive growth and a strong market presence. Despite recent stock performance, I find AptarGroup shares expensive, leading me to downgrade from 'hold' to a 'soft sell' rating. The company's financials show revenue and profitability growth, but valuation metrics indicate shares are overvalued compared to peers. AptarGroup's robust balance sheet and share buyback program are positives, but high trading multiples warrant a more cautious investment stance. Read the full article on Seeking Alpha
Nueva narrativa • Aug 25
Proprietary Drug Delivery And Digital Health Innovations To Spearhead Revenue Surge
Expansion in digital health services and sustainability initiatives may enhance brand value and open up new market opportunities, driving future growth.Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$387m |
| Dec 31 2025 | US$10m | US$1m | US$393m |
| Sep 30 2025 | n/a | n/a | US$419m |
| Jun 30 2025 | n/a | n/a | US$392m |
| Mar 31 2025 | n/a | n/a | US$370m |
| Dec 31 2024 | US$10m | US$1m | US$375m |
| Sep 30 2024 | n/a | n/a | US$336m |
| Jun 30 2024 | n/a | n/a | US$320m |
| Mar 31 2024 | n/a | n/a | US$313m |
| Dec 31 2023 | US$9m | US$1m | US$284m |
| Sep 30 2023 | n/a | n/a | US$281m |
| Jun 30 2023 | n/a | n/a | US$251m |
| Mar 31 2023 | n/a | n/a | US$232m |
| Dec 31 2022 | US$9m | US$1m | US$239m |
| Sep 30 2022 | n/a | n/a | US$238m |
| Jun 30 2022 | n/a | n/a | US$231m |
| Mar 31 2022 | n/a | n/a | US$223m |
| Dec 31 2021 | US$9m | US$1m | US$244m |
| Sep 30 2021 | n/a | n/a | US$240m |
| Jun 30 2021 | n/a | n/a | US$256m |
| Mar 31 2021 | n/a | n/a | US$243m |
| Dec 31 2020 | US$7m | US$1m | US$214m |
| Sep 30 2020 | n/a | n/a | US$209m |
| Jun 30 2020 | n/a | n/a | US$202m |
| Mar 31 2020 | n/a | n/a | US$234m |
| Dec 31 2019 | US$8m | US$1m | US$242m |
Compensación vs. Mercado: La compensación total ($USD10.23M) de Stephan está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD8.46M).
Compensación vs. Ingresos: La compensación de Stephan ha sido consistente con los resultados de la empresa en el último año.
CEO
Stephan Tanda (60 yo)
9.3yrs
Permanencia
US$10,226,911
Compensación
Mr. Stephan B. Tanda, MBA, has been an Independent Director at Ingredion Incorporated since August 19, 2019. He has been Chief Executive Officer and President at AptarGroup, Inc. since February 01, 2017. M...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 9.3yrs | US$10.23m | 0.38% $ 28.6m | |
| Executive VP & CFO | 1.3yrs | US$3.56m | 0.0020% $ 148.4k | |
| President of Aptar Pharma | no data | US$3.61m | 0.051% $ 3.9m | |
| President of Aptar Beauty | 7.7yrs | US$2.24m | 0.038% $ 2.9m | |
| Executive VP of Strategic Group Development & President of Aptar Asia | 7.6yrs | US$2.20m | 0.024% $ 1.8m | |
| President of Aptar Closures | 10yrs | US$2.62m | 0.039% $ 2.9m | |
| Senior VP & Chief Accounting Officer | 1.8yrs | sin datos | 0.051% $ 3.9m | |
| Senior Vice President of Investor Relations & Communications | no data | sin datos | sin datos | |
| Executive VP | less than a year | sin datos | 0.0023% $ 174.8k | |
| Chief Human Resources Officer | 7.5yrs | sin datos | 0.048% $ 3.6m | |
| Head of Pharma Prescription | no data | sin datos | sin datos |
7.5yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ATR es experimentado (7.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 9.3yrs | US$10.23m | 0.38% $ 28.6m | |
| Independent Director | 15yrs | US$270.99k | 0.0061% $ 460.3k | |
| Independent Director | 8.3yrs | US$296.99k | 0.014% $ 1.0m | |
| Independent Chairperson | 5yrs | US$406.02k | 0.012% $ 929.7k | |
| Independent Director | 17yrs | US$266.99k | 0.025% $ 1.9m | |
| Independent Director | 16yrs | US$283.99k | 0.012% $ 895.0k | |
| Independent Director | 3.7yrs | US$278.99k | 0.014% $ 1.1m | |
| Independent Director | 7yrs | US$266.99k | 0.011% $ 858.9k | |
| Independent Director | 3.2yrs | US$266.99k | 0.0080% $ 601.2k | |
| Independent Director | 2.7yrs | US$270.99k | 0.0069% $ 519.8k |
7.6yrs
Permanencia media
59.5yo
Promedio de edad
Junta con experiencia: La junta directiva de ATR se considera experimentada (7.6 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/13 13:30 |
| Precio de las acciones al final del día | 2026/05/13 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
AptarGroup, Inc. está cubierta por 16 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Ghansham Panjabi | Baird |
| Mark Wilde | BMO Capital Markets Equity Research |
| George Staphos | BofA Global Research |